AstraZeneca is a multinational pharmaceutical company headquartered in Cambridge, United Kingdom. It was founded in 1999 through the merger of Astra AB of Sweden and Zeneca Group plc of the United Kingdom. The company is focused on the discovery, development, and commercialization of prescription drugs, and offers a broad portfolio of products for a range of therapeutic areas, including cardiovascular, gastrointestinal, infection, neuroscience, oncology, respiratory, and other specialty care.
AstraZeneca is known for its strong commitment to research and development, and the company invests heavily in developing innovative new treatments for a range of diseases. The company is also committed to improving access to healthcare and reducing the global burden of disease, and is involved in various initiatives to improve public health, particularly in low- and middle-income countries.
In addition to its pharmaceutical operations, AstraZeneca is also involved in various initiatives to promote sustainability and social responsibility, and is widely recognized for its commitment to these values. The company is committed to reducing its environmental footprint and using sustainable ingredients, and is widely considered a leader in the pharmaceutical industry in terms of sustainability.
AstraZeneca is publicly traded and is listed on the London Stock Exchange. It is widely followed by investors and analysts, and is considered one of the largest and most successful pharmaceutical companies in the world.
In 1998, Astra AB of Sweden and Zeneca Group plc of the UK merged to form AstraZeneca. The merger created one of the world's largest pharmaceutical companies with a combined market capitalization of approximately $70 billion. The new company's portfolio included a range of innovative products, including several leading cardiovascular and respiratory drugs.
In the early 2000s, AstraZeneca focused on expanding its research and development efforts and introducing new products to the market. In 2002, the company launched Crestor, a cholesterol-lowering medication that quickly became one of its top-selling products. AstraZeneca also continued to invest in its oncology portfolio, introducing several new cancer drugs, including Iressa and Faslodex. The company's efforts were recognized with several industry awards, including the Prix Galien and the Queen's Award for Technology. By the end of the decade, AstraZeneca was well positioned as a leading global pharmaceutical company.
In 2011, AstraZeneca faced several challenges, including the expiration of patents on several key products and declining sales in Europe. The company responded by launching a major restructuring effort aimed at reducing costs and refocusing its research and development efforts on key therapeutic areas, including oncology, cardiovascular disease, and respiratory diseases. AstraZeneca also announced several partnerships and acquisitions aimed at expanding its product pipeline and research capabilities. In 2013, the company acquired biotech firm Amplimmune, which was focused on developing cancer immunotherapy treatments. AstraZeneca also formed a strategic alliance with FibroGen to develop treatments for anemia and other serious illnesses.
During the latter half of the decade, AstraZeneca continued to invest in its oncology portfolio, introducing several new cancer treatments, including Tagrisso, Lynparza, and Imfinzi. The company also made significant progress in developing treatments for chronic obstructive pulmonary disease (COPD) and launched a new asthma medication called Fasenra. In 2020, AstraZeneca partnered with the University of Oxford to develop a vaccine for COVID-19, which was authorized for emergency use in several countries around the world. Despite facing several setbacks, including the temporary suspension of clinical trials and reports of adverse reactions, AstraZeneca remained committed to developing safe and effective treatments for patients around the world.
In 2021, AstraZeneca continued its efforts to combat the COVID-19 pandemic, ramping up production of its vaccine and securing several large contracts with governments and international organizations around the world. The company also faced criticism and scrutiny over reports of blood clots and other side effects associated with the vaccine, leading to regulatory investigations and temporary suspensions in some countries. Despite these challenges, AstraZeneca maintained its commitment to developing and delivering safe and effective treatments for patients.
In addition to its COVID-19 efforts, AstraZeneca continued to make progress in its core therapeutic areas, launching new treatments for lung cancer, heart failure, and other conditions. The company also announced several partnerships and collaborations aimed at expanding its research capabilities and pipeline, including a collaboration with Regeneron to develop treatments for obesity and other metabolic disorders. Looking ahead, AstraZeneca remains focused on advancing its mission to improve the lives of patients around the world through innovative research and development in key therapeutic areas.
AstraZeneca's mission is to improve the health and well-being of people around the world. The company aims to achieve this by discovering and developing innovative medicines and vaccines that address some of the world's most pressing healthcare challenges, including cancer, respiratory diseases, cardiovascular diseases, and other conditions. AstraZeneca is committed to delivering its products to patients in need around the globe, regardless of their location or socio-economic status.
The company also strives to operate in a responsible and sustainable manner, with a focus on reducing its environmental impact, promoting diversity and inclusion in its workforce, and upholding high ethical and corporate responsibility standards. AstraZeneca's mission reflects its commitment to making a positive difference in the world by advancing healthcare and improving the lives of people everywhere.
AstraZeneca's vision is to be a leading global biopharmaceutical company that is dedicated to discovering, developing, and delivering innovative medicines and vaccines to patients around the world. The company aims to be recognized for its scientific excellence, its commitment to improving patient outcomes, and its ability to bring innovative solutions to some of the world's most pressing healthcare challenges.
AstraZeneca envisions a future where healthcare is more personalized and patient-centered, where diseases are prevented rather than treated, and where the benefits of scientific innovation are accessible to people from all walks of life. The company is committed to advancing the frontiers of science and medicine, with a focus on addressing unmet medical needs and improving the lives of people everywhere. AstraZeneca's vision reflects its ambition to be a force for good in the world, driving innovation and progress in the field of healthcare for the benefit of patients, communities, and society as a whole.
Nazneen Rahman (Non-Executive Director)
Leif Johansson (Chairman)
Andreas Rummelt (Non-Executive Director)
Pascal Soriot (CEO)
Marcus Wallenberg (Non-Executive Directo)
Aradhana Sarin (Executive Director and Chief Financial Officer)
Philip Broadley (Senior independent Non-Executive Director)
Euan Ashley (Non-Executive Director)
Michel Demaré (Non-Executive Director)
Deborah DiSanzo (Non-Executive Director)
Diana Layfield (Non-Executive Director)
Sheri McCoy (Non-Executive Director)
Tony Mok (Non-Executive Director)
AstraZeneca is a global biopharmaceutical company that develops, manufactures, and markets prescription medicines across a range of therapeutic areas. The company's products and services are organized into three main business units: BioPharmaceuticals, Oncology, and Emerging Markets.
In the BioPharmaceuticals business unit, AstraZeneca offers a broad range of medicines for the treatment of cardiovascular, metabolic, respiratory, and immunological diseases, including Crestor, a cholesterol-lowering medication, Symbicort, an inhaler used for asthma and chronic obstructive pulmonary disease, and Farxiga, a type 2 diabetes medication.
The Oncology business unit is focused on the development of innovative cancer therapies that target specific genetic mutations or cellular pathways. AstraZeneca's portfolio of oncology products includes Tagrisso, a treatment for non-small cell lung cancer, Lynparza, a PARP inhibitor for the treatment of ovarian and breast cancer, and Imfinzi, an immunotherapy medication used to treat certain types of cancer.
In Emerging Markets, AstraZeneca is focused on providing access to high-quality, affordable medicines to patients in developing countries. The company works with governments, NGOs, and other partners to improve healthcare infrastructure and increase access to medicines, including treatments for cardiovascular disease, cancer, and respiratory illness. AstraZeneca is also involved in research and development initiatives to address neglected tropical diseases and other global health challenges.The Oncology business unit is focused on the development of innovative cancer therapies that target specific genetic mutations or cellular pathways. AstraZeneca's portfolio of oncology products includes Tagrisso, a treatment for non-small cell lung cancer, Lynparza, a PARP inhibitor for the treatment of ovarian and breast cancer, and Imfinzi, an immunotherapy medication used to treat certain types of cancer.
In Emerging Markets, AstraZeneca is focused on providing access to high-quality, affordable medicines to patients in developing countries. The company works with governments, NGOs, and other partners to improve healthcare infrastructure and increase access to medicines, including treatments for cardiovascular disease, cancer, and respiratory illness. AstraZeneca is also involved in research and development initiatives to address neglected tropical diseases and other global health challenges.
Leif Johansson (Chairman)
Pascal Soriot (CEO)
Pharma and Life Sciences